MedTrace Logo

Eastern Ablation Registry for Solid Tumor (EAST)

NCT03362749 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-10-14

No results posted yet for this study

Summary

Local tumor ablation is among the major anti-tumor modalities worldwide. Given the number of changes that have taken place in the field of tumor ablation in the past 10 years, it is our intention to ensure that this highly utilized standardization continues to remain relevant as it unites all investigators and clinicians practicing interventional oncology by providing a common language to describe therapies and outcomes, develop studies, and communicate with other medical specialties. In an attempt to attain greater Asian-wide adoption, the investigators will initiate the registry system for local tumor ablation in Taiwan, China, Korea, Singapore, Hong Kong and Thailand.

Conditions

  • Solid Tumor Including Thyroid, Bone, Liver, Pancreas

Interventions

OTHER

RFA, MWA, cryo and IRE

local tumor ablation

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Kai-Wen Huang, M.D. Ph.D · National Taiwan University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2023-12-30
Completion
2023-12-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03362749 on ClinicalTrials.gov